Gene Expression, Gene Silencing, Immune Response and Trials

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Expression

Gene Silencing

Immune Response

Trials

Cash round sets up trial of InteRNA’s microRNA for cancer

pharmaphorum

FEBRUARY 9, 2021

million ($22 million) in second-round financing as it prepares to start clinical trials of its lead drug candidate INT-1B3 for solid tumours. The start of dosing in the phase 1/1b trial of the drug has been delayed by the COVID-19 pandemic, but recruitment of the target 80 participants with advanced solid tumours is reported to be ongoing.

Trials

Trials Gene Silencing RNA Gene Expression

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

DECEMBER 21, 2020

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. greater safety, transient and reversible effect on gene expression).

Genetics

Genetics Medicine Gene Therapy Marketing

Clinical Research Informer

Cash round sets up trial of InteRNA’s microRNA for cancer

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Stay Connected